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Lithium and renal tumors: a
critical comment to the report by
Zaidan et al.
To the Editor: Zaidan et al.1 reported a high prevalence of
renal tumors in tertiarily referred patients previously treated
with lithium and suffering from impaired renal function, as
compared to the prevalence in patients who had similar renal
impairment but who had not been treated with lithium. The
authors concluded that their study provided clear evidence
for a potential association between long-term lithium
treatment and an increased risk of renal solid tumors.
Owing to methodological shortcomings this interpretation is
questioned by the members of the International Group for
the Study of Lithium (IGSLi), an association of experts on
long-term treatment with lithium (http://www.igsli.org).
The study design is a case-series design and not a
‘retrospective cohort study’ as claimed by the authors. All
patients initiated on lithium (and controls) were not identified
and followed over time, implying that time at risk and
cumulative events over time were not determined. Therefore,
risks or incidence rate ratios as reported cannot be estimated.2
The observed difference in prevalence of tumors between the
two patient samples may be explained by other factors than the
effects of lithium, such as differential use of medications and
differential referral patterns. Lithium-treated patients are
generally under careful observation for renal symptoms, even
if not causally related to lithium, and non-lithium-treated
patients may suffer from even serious renal problems that
never lead to tertiary referral or renal imaging.
In conclusion, we find that no causal relation between
lithium and solid renal tumors can be inferred from the
study. Even we acknowledge that renal impairment per se
occasionally may occur after long-term lithium treatment.3
We still consider lithium as a safe treatment, provided close
monitoring is done, and as the cornerstone in the long-term
management of bipolar disorder.4
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The Authors Reply: We thank Licht et al.1 for their interest
in our study on the increased prevalence of renal tumors in
lithium-treated patients with chronic kidney disease (CKD).2
Licht et al. raised some concerns about the study design.1
In the first part of our study, we identified all patients treated
with lithium for bipolar disorder and regularly followed up
for their CKD at the outpatient clinic. Thus, lithium expo-
sure was ascertained. Then, we compared the proportion of
renal tumors between lithium-treated and gender-, age-, and
estimated glomerular filtration rate–matched lithium-free
patients, sampled from the unexposed patients followed in
our departments, and showed that it was greater in lithium-
treated patients.2 Contrary to what Licht et al. mentioned, we
did not estimate relative risks and incidence rate ratios
between the two groups. Instead, we calculated the number of
expected cases of renal cancer in lithium-treated patients by
gender and for each 5-year stratum using the French national
estimates of renal cancer,3 and showed increased standardized
incidence ratios of renal cancers in lithium-treated patients
compared to the general population. Collectively, we repor-
ted an association and not a causal effect.4 Moreover, our
results cannot be generalized to all lithium-treated patients
because we did not explore a large population of lithium-
treated patients without CKD. Finally, our work does not
question the benefit of lithium in the management of
bipolar disorders, but alerts nephrologists and psychiatrists
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